Norway Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Norway Breast Cancer Therapeutics Market Analysis

$ 3999

The Norway breast cancer therapeutics market is expected to grow from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of xx% for the year 2022-2030. The main market drivers for Norway's breast cancer therapeutics market are increased research and development initiatives and growing awareness of breast cancer therapeutics. The market is segmented by therapy, by cancer type, and by distribution channel. Norsk Pharma, AbbVie, and Amgen are some of the leading companies in the Norway breast cancer therapeutics market.

ID: IN10NOPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Norway AUTHOR: Parul Choudhary

Buy Now

Norway Breast Cancer Therapeutics Market Executive Analysis

The Norway breast cancer therapeutics market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period. The general government funded the largest portion of Norway's health spending in 2021, which came to about $36.49 Bn. The general government, excluding social health insurance, contributed the second-largest sum, or around $32.10 Bn. Norway is one of the countries in the world that spends the most on healthcare, allocating 10.1% of its GDP to this sector. Totaling 43 Bn, which works out to 7,900 per citizen in 2021. In a time of budgetary restraints, a rise in chronic diseases, and an aging population, the state-run healthcare system—which pays for 85% of all healthcare expenses—strives for organizational and technological advancements.

In Norway, breast cancer affects one in every eleven women under the age of 75. In Norway, there were 138 breast cancer cases reported per 100,000 women in 2019. Over the specified time period, the number of newly diagnosed cases of breast cancer has generally grown. In Norway, mammography is used for breast cancer screening, which is supervised by the Norwegian Cancer Registry and typically begins when a woman turns 50. However, women under the age of 50 account for 20% of all instances of breast cancer.

The most aggressive form of breast cancer is known as Triple-Negative Breast Cancer (TNBC), which is defined by the lack or low expression of the hormone receptors for progesterone, oestrogen, and Human Epidermal Growth Factor (HER2). TNBC, which makes up 15% of breast cancer cases in Norway, is infamous for having a high relapse rate and a dismal overall survival rate. Chemo-resistant TNBC is a genetically complex, extremely heterogeneous, and quickly developing illness that makes it difficult to individually tailor treatment for individuals who have relapsed or had inadequate responses. To treat high-risk and locally advanced TNBC, the frontline standard chemotherapy, which consists of anthracyclines, alkylating agents, and taxanes, is frequently employed.

Market Dynamics

Market Growth Drivers

The primary growth drivers for the Norway breast cancer therapeutics market over the projected period will be an increase in research and development investment for novel treatments, frequent Corporate Social Responsibility (CSR) initiatives to raise breast cancer awareness, and mergers and acquisitions between the companies.

Market Restraints

The significant capital expenditures required for R&D and the duration of time it takes for medications to receive approval are the main obstacles to entry and long-term sustained growth in the Norway breast cancer therapeutics market.

Competitive Landscape

Key Players

Xellia Pharmaceuticals (NOR)
Curida (NOR)
ACD Pharma (NOR)
Norsk Pharma (NOR)
AbbVie
Amgen
Astellas Pharma
AstraZeneca

Healthcare Policies and Regulatory Landscape

Norway offers free healthcare to all citizens, and it is primarily supported by general taxes and payroll contributions that both employers and employees split equally. It is automatic to enroll. Primary, ambulatory, mental health, hospital, as well as a few outpatient prescription medications, are all covered services. Patients must pay co-payments for some services and goods, and most services have limits on their out-of-pocket expenses. The national healthcare system in Norway, which is financed by taxes, covers breast cancer treatment. This implies that all citizens of Norway, regardless of their level of income or insurance coverage, are covered for the cost of all forms of treatment, including surgery, radiation therapy, and chemotherapy. The Norwegian Breast Cancer Group (NBCG), which is in charge of creating treatment protocols and standards, offers advice on breast cancer screening and treatment in Norway.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Norway Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.